These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11679189)

  • 1. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer.
    Langer CJ
    Lung Cancer; 2001 Nov; 34(2):297-303. PubMed ID: 11679189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
    Minsky BD
    Int J Cancer; 2001 Feb; 96(1):1-10. PubMed ID: 11241325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
    Hoff PM
    Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UFT in the treatment of colorectal and breast cancer.
    Sun W; Haller D
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):49-56. PubMed ID: 11219978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
    Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
    J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
    Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
    Feliu J; González Barón M; Zamora P; Garcia Alfonso P; Garcia Girón C; Blanco E; Belón J; Garrido P; Jara C; Ruiz A; Vincent JM; Espinosa E
    Oncology; 1997; 54 Suppl 1():30-7. PubMed ID: 8978582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer.
    Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S
    Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UFT and S-1 for treatment of primary lung cancer.
    Tanaka F; Wada H; Fukushima M
    Gen Thorac Cardiovasc Surg; 2010 Jan; 58(1):3-13. PubMed ID: 20058135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of UFT combined with 5 consecutive days cisplatin in non-small cell lung cancer.
    Koinumaru S; Matsuda T; Saitoh J; Nakai Y
    Lung Cancer; 1997 Nov; 18(3):241-51. PubMed ID: 9444649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
    Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
    Hoff PM; Lassere Y; Pazdur R
    Drugs; 1999; 58 Suppl 3():77-83. PubMed ID: 10711845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
    Rustum YM
    Oncology; 1997; 54 Suppl 1():7-11. PubMed ID: 8978578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
    J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):48-50. PubMed ID: 10442361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.